List of 9 ALK Inhibitors

List of 9 ALK inhibitor drugs currently in clinical trials:

FDA approved (but several trials ongoing)
Novartis – Ceritinib
Pfizer – Crizotinib

FDA Breakthrough Status
Chugai – Alectinib (filed NDA in Japan)

Ongoing trials
Ariad AP26113
Nerviano NMS-E628. (Licensed by Ignyta and renamed RXDX-101)
Pfizer PF-06463922
Tesaro TSR-011
Teva CEP-37440
Xcovery x-396

Discontinued Research
Astellas ASP-3026

This entry was posted in alectinib - Alecensa from Chugai - Roche - GenenTech, brigatinib-Alunbrig from Takeda, CEP-37440, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, NMS-E628, Potential Treatments, Regulatory applications & approvals, Research, RXDX-101 - entrectinib - by Ignyta, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery. Bookmark the permalink.

Leave a Reply